Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1781
Name thyroid gland cancer
Definition An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.
Source DiseaseOntology.org
Alt Ids DOID:10008
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid gland cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Axitinib thyroid gland cancer not applicable detail...
BRAF act mut Vemurafenib thyroid gland cancer sensitive detail...
BRAF mutant Selumetinib thyroid gland cancer predicted - sensitive detail...
Unknown unknown Bevacizumab thyroid gland cancer not applicable detail...
Unknown unknown Cetuximab thyroid gland cancer not applicable detail...
Unknown unknown Bevacizumab + Cetuximab thyroid gland cancer not applicable detail...
NRAS mutant Selumetinib thyroid gland cancer sensitive detail...
BRAF V600E Lapatinib + Vemurafenib thyroid gland cancer sensitive detail...
HRAS inact mut BEZ235 thyroid gland cancer sensitive detail...
Unknown unknown Lenvatinib thyroid gland cancer not applicable detail...
FGFR1 over exp Lenvatinib thyroid gland cancer sensitive detail...
RET C634W Lenvatinib thyroid gland cancer sensitive detail...
Unknown unknown Sorafenib thyroid gland cancer not applicable detail...
BRAF V600X Vemurafenib thyroid gland cancer predicted - sensitive detail...
BRAF V600E CLM3 thyroid gland cancer sensitive detail...
BRAF wild-type CLM3 thyroid gland cancer sensitive detail...
Unknown unknown CLM3 thyroid gland cancer not applicable detail...
Unknown unknown ABT-737 thyroid gland cancer not applicable detail...
Unknown unknown ABT-737 + Doxorubicin thyroid gland cancer not applicable detail...
Unknown unknown ABT-737 + Gemcitabine thyroid gland cancer not applicable detail...
Unknown unknown ABT-737 + Cisplatin thyroid gland cancer not applicable detail...
BRAF V600E BGB-283 thyroid gland cancer sensitive detail...
RET C634W Regorafenib thyroid gland cancer sensitive detail...
BRAF V600E Trametinib thyroid gland cancer predicted - sensitive detail...
BRAF V600E Selumetinib thyroid gland cancer sensitive detail...
BRAF V600E Dasatinib + Trametinib thyroid gland cancer sensitive detail...
BRAF V600E Dasatinib + Selumetinib thyroid gland cancer sensitive detail...
BRAF V600E Dasatinib + SCH772984 thyroid gland cancer sensitive detail...
BRAF V600E TAK-632 thyroid gland cancer sensitive detail...
BRAF V600E Vemurafenib thyroid gland cancer conflicting detail...
RET C634W AZD1480 thyroid gland cancer sensitive detail...
PIK3CA H1047R MK2206 thyroid gland cancer sensitive detail...
HRAS G13R MK2206 thyroid gland cancer sensitive detail...
NRAS Q61R MK2206 thyroid gland cancer sensitive detail...
PIK3CA E545K MK2206 thyroid gland cancer sensitive detail...
PIK3CA H1047R MK2206 + Temsirolimus thyroid gland cancer sensitive detail...
Unknown unknown SNS-314 thyroid gland cancer not applicable detail...
Unknown unknown SL327 + Sunitinib thyroid gland cancer not applicable detail...
Unknown unknown LY2874455 thyroid gland cancer not applicable detail...
Unknown unknown Everolimus thyroid gland cancer not applicable detail...
BRAF mutant Belvarafenib thyroid gland cancer sensitive detail...
BRAF act mut Dabrafenib thyroid gland cancer sensitive detail...
RET fusion Selpercatinib thyroid gland cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01182285 Phase II liothyronine sodium Valproic acid A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin Completed
NCT01236547 Phase II Paclitaxel Pazopanib Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Active, not recruiting
NCT01240590 Phase Ib/II Cisplatin + Crolibulin Cisplatin A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Completed
NCT01263951 Phase II Everolimus + Sorafenib Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Completed
NCT01270321 Phase II Pasireotide Everolimus A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer Completed
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed
NCT01811212 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed
NCT01843062 Phase III Selumetinib Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer Terminated
NCT01876784 Phase III Vandetanib Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Active, not recruiting
NCT01947023 Phase I Dabrafenib + Lapatinib Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT02012231 Phase Ib/II PLX8394 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT02041260 Phase II Cabozantinib A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Active, not recruiting
NCT02143726 Phase II Sorafenib Everolimus Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer Active, not recruiting
NCT02244463 Phase II Sapanisertib A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer Recruiting
NCT02289144 Phase II Ceritinib Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer Withdrawn
NCT02383927 Phase II Tipifarnib Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations Recruiting
NCT02432274 Phase Ib/II Etoposide Lenvatinib Cyclophosphamide Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies Completed
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting
NCT02657369 Phase II Lenvatinib A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) Terminated
NCT02688608 Phase II Pembrolizumab Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Recruiting
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting
NCT02973997 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03002623 Phase II CUDC-907 CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer Terminated
NCT03065387 Phase I Everolimus + Neratinib Neratinib + Palbociclib Neratinib + Trametinib Study of the Pan-ERBB InhibStudy of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation Recruiting
NCT03085056 Phase I Paclitaxel + Trametinib Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer Recruiting
NCT03099356 Phase II Cyclophosphamide + Sirolimus Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer Suspended
NCT03122496 Phase I Durvalumab + Tremelimumab Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer Active, not recruiting
NCT03131206 Phase Ib/II Alectinib A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Terminated
NCT03139747 Phase II Everolimus + Lenvatinib UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone Completed
NCT03211117 Phase II Docetaxel + Doxorubicin + Pembrolizumab Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer Completed
NCT03246958 Phase II Ipilimumab + Nivolumab Nivolumab Plus Ipilimumab in Thyroid Cancer Recruiting
NCT03360890 Phase II Docetaxel + Pembrolizumab Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Recruiting
NCT03506048 Phase II Lenvatinib Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Recruiting
NCT03630120 Phase II Lenvatinib + Sorafenib Cabozantinib + Vandetanib Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Active, not recruiting
NCT03690388 Phase III Cabozantinib A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy Recruiting
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Active, not recruiting
NCT03975231 Phase I Dabrafenib + Trametinib Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer Not yet recruiting
NCT04061980 Phase II Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer Not yet recruiting
NCT04321954 Phase II Lenvatinib Lenvatinib in Locally Advanced Invasive Thyroid Cancer Not yet recruiting